CytRx Corporation (CYTR) To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
4/28/2014 9:01:59 AM
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will be presenting updated progression-free survival and overall survival results from its completed Phase 1b/2 clinical trial of aldoxorubicin in soft tissue sarcoma. The trial was conducted at the Sarcoma Oncology Center in Santa Monica, California.
Help employers find you! Check out all the jobs and post your resume.
comments powered by